BMY vs NBIX · P/E 17, rev $24.46B vs P/E 45, rev $1.77B
Bristol-Myers Squibb Company (BMY) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the BMY and NBIX stock pages for the full models.
Not investment advice.